MCM
JUNO

Mazama Capital Management’s Juno Therapeutics, Inc. JUNO Stock Holding History

Mazama Capital Management’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-476
Closed -$21K – 236
2015
Q4 		$21K Buy
476
+125
+36% +$6.2K ﹤0.01% 253
2015
Q3 		$14K Buy
+351
New +$15.4K ﹤0.01% 265
2015
Q1 		– Sell
-500
Closed -$26K – 311
2014
Q4 		$26K Buy
+500
New +$22.4K 0.01% 255

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BCM
Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Mazama Capital Management's JUNO Position: Q1 2016 in Review

Mazama Capital Management sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2016, closing a stake of 476 shares — an estimated $21K sold.

Mazama Capital Management first reported a position in JUNO in Q4 2014 and held it in 3 quarters. The position peaked at $26K in Q4 2014. 158 funds tracked by Wall St. Rank hold JUNO as of Q1 2016.

  • Mazama Capital Management reported no remaining Juno Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
  • Mazama Capital Management sold 476 Juno Therapeutics, Inc. shares in Q1 2016, an estimated $21K.
  • Mazama Capital Management first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 3 quarters.
  • Mazama Capital Management's Juno Therapeutics, Inc. position peaked at $26K in Q4 2014.
  • 158 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2016.

Based on Mazama Capital Management's 13F filing for Q1 2016.